Weekly ReportAug 31 – Sep 6, 2026
Sepsis, week 36 edition
We read 235 papers and selected 3.
Summary
This week’s sepsis literature advanced three major fronts: precision targeting of dysregulated host responses, modernization of diagnosis and severity assessment, and pragmatic improvement of antimicrobial and resuscitation practices. Highly innovative preclinical studies identified extracellular histones, neutrophil extracellular traps, IL-39, neuroimmune circuits, and metabolic stress pathways as therapeutic targets, while clinical studies supported updated risk scoring, balanced crystalloids, tissue-based metagenomic diagnosis, and antibiotic stewardship. The development of SOFA-2 and its external emergency-department validation signal a potential paradigm shift in how organ dysfunction is quantified, although clinical-impact studies remain necessary. Overall, the field is moving toward biologically stratified treatment combined with faster, more context-aware diagnosis and implementation.
Selected Articles
1. Sequential clearance of neutrophil extracellular traps for precision therapy of sepsis.
This study developed MOF818, a multifunctional nanocomposite combining antioxidant activity, NET capture, and micrococcal nuclease-mediated NET degradation. The platform reduced NETosis and inflammatory injury in vitro, improved cytokine profiles, organ damage, and survival in septic mice, and showed anti-NET activity in ex vivo human sepsis specimens.
Impact: The study addresses both ongoing NET production and pre-existing NET structures, offering a more comprehensive strategy than single-target NET inhibition. It also provides a translational bridge through ex vivo human specimens, although clinical efficacy and safety remain untested.
Clinical Implications: MOF818 suggests a future adjunctive therapy for NET-dominant sepsis with microthrombosis and organ dysfunction. Before clinical translation, pharmacokinetics, biodistribution, immunogenicity, toxicity, effects on pathogen clearance, and large-animal efficacy must be established.
Key Findings
- MOF818 combined reactive oxygen species scavenging, electrostatic NET capture, and enzymatic DNA degradation.
- Treatment reduced NET-mediated inflammation and improved organ injury and survival in murine sepsis.
- Ex vivo human sepsis specimens showed reduced NETosis and inflammatory cytokine production after treatment.
2. 4-phenylbutyric acid alleviated sepsis-induced myocardial dysfunction by inhibition of MAM formation to improve mitochondrial dynamic balance in myocardial cells.
In experimental sepsis, 4-phenylbutyric acid improved myocardial function by inhibiting mitochondria-associated membrane formation and restoring mitochondrial dynamics. The proposed mechanism involved suppression of HK2-dependent glycolysis, reduced Arpc1b-K308 lactylation, and direct interaction with HK2 catalytic sites.
Impact: This study connects endoplasmic reticulum stress, glycolytic metabolism, protein lactylation, mitochondria-associated membranes, and septic cardiomyopathy in one mechanistic pathway. It identifies 4-phenylbutyric acid and HK2-related signaling as experimentally testable therapeutic strategies.
Clinical Implications: The findings support further preclinical development of 4-phenylbutyric acid for septic cardiomyopathy, but they do not justify clinical use. Human studies must establish dosing, pharmacokinetics, toxicity, and effects on survival and cardiac function.
Key Findings
- 4-phenylbutyric acid significantly alleviated sepsis-induced myocardial dysfunction.
- Cardioprotection was associated with inhibition of mitochondria-associated membrane formation and restoration of mitochondrial dynamics.
- The mechanism involved HK2 inhibition, reduced Arpc1b-K308 lactylation, and interaction with HK2 catalytic sites.
3. Why a new Sequential Organ Failure Assessment score: rationale and development of Sequential Organ Failure Assessment-2.
SOFA-2 was developed through a modified Delphi process involving 60 international experts, systematic reviews, and multinational database analyses. It retains the original six organ systems while updating thresholds, incorporating contemporary organ-support modalities, and standardizing missing-data and acute-on-chronic dysfunction handling.
Impact: SOFA is embedded in sepsis definitions, intensive care research, clinical documentation, and benchmarking. A rigorously developed update could influence future diagnostic criteria, trial eligibility, risk stratification, and international reporting, although outcome impact remains unproven.
Clinical Implications: SOFA-2 may provide a more contemporary and standardized measure of organ dysfunction. It should currently be viewed as a validated framework in development rather than an automatic replacement for SOFA-1, and implementation should await broader validation and clinical-impact studies.
Key Findings
- SOFA-2 was developed using a modified Delphi process with 60 international experts.
- The six original organ systems were retained, with updated definitions and contemporary organ-support criteria.
- Gastrointestinal and immune domains were not included because supporting datasets were insufficient.